Best Lentiviral Vector CDMOs by Signal Score

← All Lentiviral CDMOs Best Clean FDA History Commercial Scale

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

Lentiviral vectors are the workhorse of ex vivo gene therapy, used to engineer T cells for CAR-T and to modify hematopoietic stem cells. Because the vector ends up in patient-bound cells, manufacturers carry the regulatory weight of a critical starting material under full GMP.

Choosing a lentiviral vector CDMO comes down to BSL-2 containment, a mature suspension or adherent platform, robust analytics (titer, potency, RCL testing), and a clean regulatory record. The rankings below score each CDMO on FDA inspection history, GMP certification, clinical-program activity, and capacity signals.

FDA inspection outcomes across these CDMOs: 9 NAI (no action), 11 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (23), United States (20), Denmark (18), Germany (7), France (4).

Last updated 2026-05-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	91.7	98.7	7 insp · 11 GMP	Limited	0 programs
2	RP ReciBioPharm Keele, UK · Sodertalje, SE	88.0	100.0	0 insp · 3 GMP	—	0 programs
3	PB Pharmaron Biologics San Diego, CA · Shaoxing, CN	85.6	100.0	3 insp · 0 GMP	—	0 programs
4	TF Thermo Fisher Scientific Plainville, MA · Alachua, FL · Cambridge, MA	83.1	97.9	5 insp · 10 GMP	Available	2 programs
5	BR BioReliance (Merck) Glasgow, UK · Rockville, MD	81.0	98.8	2 insp · 8 GMP	—	0 programs
6	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	1 insp · 23 GMP	Available	2 programs
7	OB OmniaBio Hamilton, ON	79.5	100.0	0 insp · 2 GMP	—	0 programs
8	PG ProBioGen Berlin, DE	78.9	100.0	0 insp · 2 GMP	—	0 programs
9	BB bluebird bio Manufacturing Durham, NC	78.5	—	—	—	0 programs
10	Lonza Basel, Switzerland	78.2	95.1	2 insp · 8 GMP	—	1 programs

How we score CDMOs →

What to evaluate in a Lentiviral Vector CDMO

Containment & biosafety

Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.

Process platform maturity

Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.

Analytics & potency

Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.

Lentiviral Vector CDMOs — Frequently Asked Questions

Who are the top Lentiviral Vector CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Lentiviral Vector CDMOs include Charles River Laboratories, ReciBioPharm, Pharmaron Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Lentiviral Vector CDMOs have FDA inspection records?

CDMO Signal tracks 6 Lentiviral Vector CDMOs with FDA inspection records and 67 EMA/MHRA GMP certificates across the group.

What should I look for in a lentiviral vector CDMO?

Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.

How is lentiviral vector manufacturing different from AAV?

Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.

Related modalities

Cell Therapy CDMOs CAR-T CDMOs AAV / Gene Therapy CDMOs

Other Modalities

AAV CAR-T Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC